Sucampo Pharma (SCMP) Misses Q1 EPS by 17c, Reiterates FY Guidance

Sucampo Pharma (NASDAQ: SCMP) reported Q1 EPS of $0.10, $0.17 worse than the analyst estimate of $0.27. Revenue for the quarter came in at $56.3 million versus the consensus estimate of $54.14 million.

Sucampo today reiterated its guidance for the full year ending December 31, 2017. Sucampo expects total revenue of $220.0 million to $230.0 million, adjusted net income of $56.0 million to $66.0 million, adjusted EPS of $1.00 to $1.10, adjusted EBITDA of $109.0 million to $119.0 million and free cash flow of $86.0 million to $96.0 million.

For earnings history and earnings-related data on Sucampo Pharma (SCMP) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
• Innovaro (INV) Misses Q2 EPS by 9c